Read More

Medical Device Player Beyond Air’s Subsidiary Reveals Encouraging Data From Early-Stage Cancer Study

Beyond Cancer Ltd, an affiliate of Beyond Air Inc (NASDAQ: XAIR), announced that the Phase 1 Study evaluating ultra-high concentration nitric oxide (UNO) in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors has cleared the

XAIR